St. Jude Medical Inc. (NYSE:STJ) saw unusually-high trading volume on Friday . Approximately 2,880,736 shares traded hands during mid-day trading, an increase of 70% from the previous session’s volume of 1,692,161 shares.The stock last traded at $82.98 and had previously closed at $82.92.

STJ has been the topic of a number of research analyst reports. Canaccord Genuity set a $85.00 price target on shares of St. Jude Medical and gave the stock a “hold” rating in a report on Wednesday, July 20th. Barclays PLC downgraded shares of St. Jude Medical from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $74.00 to $80.00 in a report on Wednesday, May 11th. Needham & Company LLC downgraded shares of St. Jude Medical from a “buy” rating to a “hold” rating in a report on Friday, April 29th. Zacks Investment Research raised shares of St. Jude Medical from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a report on Friday, April 22nd. Finally, Leerink Swann reissued a “hold” rating and issued a $85.00 price target on shares of St. Jude Medical in a report on Thursday, July 21st. Twenty-two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. St. Jude Medical has an average rating of “Hold” and an average target price of $75.93.

The stock has a market cap of $23.64 billion and a PE ratio of 36.08. The stock has a 50-day moving average of $81.98 and a 200 day moving average of $68.85.

St. Jude Medical (NYSE:STJ) last posted its quarterly earnings results on Wednesday, July 20th. The medical technology company reported $1.06 EPS for the quarter, hitting the Zacks’ consensus estimate of $1.06. The business earned $1.56 billion during the quarter, compared to analysts’ expectations of $1.55 billion. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.07 earnings per share. On average, equities analysts forecast that St. Jude Medical Inc. will post $4.06 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 30th will be issued a $0.31 dividend. The ex-dividend date of this dividend is Wednesday, September 28th. This represents a $1.24 dividend on an annualized basis and a yield of 1.49%.

A number of hedge funds and institutional investors have bought and sold shares of the company. Dorsey & Whitney Trust CO LLC boosted its position in St. Jude Medical by 6.9% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 54,103 shares of the medical technology company’s stock worth $3,343,000 after buying an additional 3,484 shares in the last quarter. Advisors Asset Management Inc. boosted its position in St. Jude Medical by 32.6% in the fourth quarter. Advisors Asset Management Inc. now owns 20,002 shares of the medical technology company’s stock worth $1,236,000 after buying an additional 4,916 shares in the last quarter. BlackRock Advisors LLC boosted its position in St. Jude Medical by 0.7% in the fourth quarter. BlackRock Advisors LLC now owns 2,322,921 shares of the medical technology company’s stock worth $143,486,000 after buying an additional 15,602 shares in the last quarter. Principal Financial Group Inc. boosted its position in St. Jude Medical by 4.3% in the fourth quarter. Principal Financial Group Inc. now owns 432,163 shares of the medical technology company’s stock worth $26,694,000 after buying an additional 17,640 shares in the last quarter. Finally, Bridgewater Associates LP boosted its position in St. Jude Medical by 39.8% in the fourth quarter. Bridgewater Associates LP now owns 77,167 shares of the medical technology company’s stock worth $4,767,000 after buying an additional 21,951 shares in the last quarter.

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.